Table 1.

Summary of common inputs used by the models [adapted from Mandelblatt et al. (40)]^a

Name	Description	Source
Population demographics and other-cause mortality
Population demographic characteristics	Cross-sectional female population in US organized by birth cohorts	US census data (34)
Other-case mortality	Death from other causes	CDC WONDER Database (41)
Natural history
Incidence in absence of screening	Breast cancer incidence in absence of screening and treatment	Age-period-cohort models (42, 43)
Survival in absence of screening and  treatment	25-y breast cancer survival before adjuvant treatment by joint ER/HER2 status, age group, AJCC/SEER stage, or tumor size	Meta-analyses (44)
Stage distribution	Stage distributions by mode of detection, age group (<50, 50-64, >65 y), screening round (first, subsequent), and screening interval	BCSC (40, 45)
ER/HER2 joint distribution	Probability of ER/HER2 conditional on age and stage/tumor size at diagnosis	BCSC (40, 45)
Screening and diagnosis
Mammography rates	Use of mammography by different ages over time	NHIS, BCSC (40, 45, 46)
Mammography performance	Sensitivity of initial and subsequent digital mammography by age group (<50, 50-64, >65 y) and screening interval	BCSC (40, 45)
Treatment
Treatment patterns	Treatments and rates of use by time period, ER/HER2, stage and age at time of breast cancer diagnosis	NCCN and meta-analyses (40, 47)
Treatment effects	Treatment efficacy by ER/HER2 for initial breast cancer diagnosis	Meta-analyses and clinical trial results (48–53)

^aAJCC = American Joint Committee on Cancer; BCSC = Breast Cancer Surveillance Consortium; CDC = Centers for Disease Control and Prevention; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; NCCN = National Comprehensive Cancer Network; NHIS = National Health Information Survey; SEER = Surveillance, Epidemiology, and End Results; WONDER = Wide-ranging ONline Data for Epidemiologic Research.